All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MDS Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL hub

ALL hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site aml-hub.com.
2020-06-30T14:05:38.000Z

Is azacitidine + APR-246 safe and effective in TP53 mutated MDS and AML?

By Claire Baker, Amalia Zachariadis
Featured
Thomas Cluzeau
Jun 30, 2020
Share:

Bookmark this article

During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Thomas Cluzeau, Centre Hospitalier Universitaire de Nice, Nice, FR. We asked: Is azacitidine + APR-246 safe and effective in patients with TP53 mutated MDS and acute myeloid leukemia?

Is azacitidine + APR-246 safe and effective in TP53 mutated MDS and AML?

Results from the phase II study, evaluating the novel p53-activating drug, APR-246, + azacitidine for the treatment of patients with TP53 mutated MDS and acute myeloid leukemia, were presented at this year's EHA meeting. The combination has demonstrated a manageable toxicity profile and promising clinical efficacy in this setting.

More about...
AzacitidineEHAEHA 2020EprenetapoptTP53

Related articles

Add bookmark

Eprenetapopt with azacitidine for TP53-mutant MDS/AML: Results from two ongoing clinical trials

Patients with TP53-mutant myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience suboptimal responses to currently available...

Mar 19, 2021
Add bookmark

Eprenetapopt with azacitidine for TP53-mutant MDS/AML: Results from two ongoing clinical trials

Patients with TP53-mutant myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience...

Mar 19, 2021
Add bookmark

Targeted therapeutics in MDS – what’s the current state of play?

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub podcast channel spoke to Dr David Sallman, Moffitt Cancer Center, Tampa, US, and Professor Amer...

Nov 10, 2020
Add bookmark

Targeted therapeutics in MDS – what’s the current state of play?

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub podcast channel spoke to Dr David Sallman,...

Nov 10, 2020

Newsletter

Subscribe to get the best content related to MDS delivered to your inbox